AstraZeneca PLC (NASDAQ:AZN) Position Trimmed by Lindbrook Capital LLC

Lindbrook Capital LLC trimmed its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 8.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,889 shares of the company’s stock after selling 692 shares during the period. Lindbrook Capital LLC’s holdings in AstraZeneca were worth $615,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Norden Group LLC bought a new position in AstraZeneca during the 1st quarter worth $255,000. Oppenheimer & Co. Inc. grew its position in shares of AstraZeneca by 10.2% during the first quarter. Oppenheimer & Co. Inc. now owns 18,268 shares of the company’s stock worth $1,238,000 after acquiring an additional 1,694 shares during the last quarter. Atomi Financial Group Inc. increased its holdings in shares of AstraZeneca by 41.2% in the 1st quarter. Atomi Financial Group Inc. now owns 14,295 shares of the company’s stock worth $969,000 after acquiring an additional 4,172 shares during the period. Concurrent Investment Advisors LLC lifted its position in AstraZeneca by 17.7% in the 1st quarter. Concurrent Investment Advisors LLC now owns 3,498 shares of the company’s stock valued at $237,000 after purchasing an additional 525 shares during the last quarter. Finally, Choate Investment Advisors boosted its stake in AstraZeneca by 59.5% during the 1st quarter. Choate Investment Advisors now owns 5,363 shares of the company’s stock valued at $363,000 after purchasing an additional 2,000 shares during the period. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Price Performance

Shares of AZN opened at $64.49 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89. The firm has a market cap of $199.96 billion, a PE ratio of 31.15, a PEG ratio of 1.19 and a beta of 0.47. The firm’s 50 day moving average price is $77.07 and its 200 day moving average price is $78.56. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68.

Analysts Set New Price Targets

A number of research firms have recently weighed in on AZN. TD Cowen lifted their price target on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday. Finally, Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, AstraZeneca presently has an average rating of “Buy” and an average price target of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.